VERV Verve Therapeutics

Watchlist

5.490
-0.290-5.02%

Trading Mar 25 10:10 ET

487.49MMarket Cap-2.34P/E (TTM)

Verve Therapeutics Key Stats

According to the latest financial report of Verve Therapeutics, the latest earnings per share (TTM) for the company is -0.58. Investing in companies with strong earnings per share can potentially provide higher returns.

Currency: USD

Quarterly

FCF

Interested in knowing about Verve Therapeutics's free cash flow? The latest report shows it as -42.23M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.

Currency: USD

Quarterly

Current Ratio

If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Verve Therapeutics shows that the company's current ratio is 12.65, indicating healthy liquidity.

Currency: USD

Quarterly

Quick Ratio

Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Verve Therapeutics, the quick ratio is 12.29, indicating that the company can meet its short-term debt obligations.

Currency: USD

Quarterly

ROE

Want to learn more about the financial health of Verve Therapeutics? The latest ROE figure is -9.99%, indicating that the company has stable profitability.

Currency: USD

Quarterly

ROA

Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Verve Therapeutics, the total asset return on investment (ROA) is -7.63%.

Currency: USD

Quarterly

Gross Margin

Gross margin can provide insight into a company's pricing strategy and cost structure. Check Verve Therapeutics's latest financial report to see how their gross margin is doing - currently at --.

Currency: USD

Quarterly

Net Margin

For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Verve Therapeutics, the net profit margin is -382.53%, which is a good sign for its profitability.

Currency: USD

Quarterly

Market Insights